Figure 1
Figure 1. Cumulative incidences of cardio-vascular events occurring in CP CML pts on Ponatinib or on Nilotinib since TKI initiation and on each TKI.

Cumulative incidences of cardio-vascular events occurring in CP CML pts on Ponatinib or on Nilotinib since TKI initiation and on each TKI.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal